Our Team

Brandon has spent over 25 years on Wall Street focused on biotech investing and analysis. He has founded two publicly traded companies. His interest in ketamine began in 2012 when he identified it as one of the most promising and underutilized medicines in modern healthcare. He began studying its mechanisms in depth, and by 2013 was involved in its first clinical applications. He predicted the commercial success of Spravato — a ketamine-based antidepressant — more than a billion dollars in sales before it launched. The EPIK platform is built directly from that decade-plus of research and expertise.

Dr. Dunn is a board-certified anesthesiologist trained at Mayo Clinic Arizona. He brings deep clinical expertise in pain management and ketamine therapeutics. He has advised Pacira Biosciences, a publicly traded pharmaceutical company (Nasdaq: PCRX), and has extensive experience designing and executing clinical trials and treatment protocols.